Morise Masahiro

モリセマサヒロ | Morise Masahiro

Affiliation and department：
Job title： Lecturer of hospital

Research keywords (3)：化学療法に関する支持療法 , 悪性胸膜中皮腫 , 肺癌

Research theme for competitive and other funds (13)：

2019 - 2022 進行肺癌の血漿遊離DNAを利用したマルチ遺伝子解析法に基づく個別化医療の確立を目指した研究(AMED)
2019 - 2022 呼吸器悪性腫瘍における血管新生阻害治療の低侵襲な効果予測法を確立をめざす研究
2018 - 2021 ROS1融合遺伝子陽性の進行固形がんに対する治療開発を目指した研究 (AMED)
2019 - 2020 希少遺伝子変異を有する小細胞肺癌に対する新規治療法の確立に関する研究 (AMED)
2018 - 2020 RET肺がんに対するアレクチニブの医師主導治験と耐性機構解析 (AMED)

Show all

Papers (33)：

Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, et al. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clin Lung Cancer. 2019. 20. 6. 442-450
Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya, et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International journal of clinical oncology. 2019. 24. 7. 731-770
Ichidai Tanaka, Masahiro Morise, Yuta Kodama, Akira Matsui, Naoya Ozawa, Sachiko Ozone, Daiki Goto, Ayako Miyazawa, Tetsunari Hase, Naozumi Hashimoto, et al. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer. 2019. 127. 169-171
Mitsuo Sato, Akira Matsui, Yoshie Shimoyama, Norihito Omote, Masahiro Morise, Tetsunari Hase, Ichidai Tanaka, Kojiro Suzuki, Yoshinori Hasegawa. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Internal Medicine. 2018. 57. 23. 3429-3432
Ichidai Tanaka, Mitsuo Sato, Toshio Kato, Daiki Goto, Tomohiko Kakumu, Ayako Miyazawa, Naoyuki Yogo, Tetsunari Hase, Masahiro Morise, Yoshitaka Sekido, et al. eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Science. 2018. 109. 6. 1843-1852

ｍore...

MISC (29)：

Mitsuo Sato, Akira Matsui, Yoshie Shimoyama, Norihito Omote, Masahiro Morise, Tetsunari Hase, Ichidai Tanaka, Kojiro Suzuki, Yoshinori Hasegawa. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Internal Medicine. 2018. 57. 23. 3429-3432
Ichidai Tanaka, Mitsuo Sato, Toshio Kato, Daiki Goto, Tomohiko Kakumu, Ayako Miyazawa, Naoyuki Yogo, Tetsunari Hase, Masahiro Morise, Yoshitaka Sekido, et al. eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Science. 2018. 109. 6. 1843-1852
Shotaro Okachi, Kazuyoshi Imaizumi, Naoyuki Imai, Takahiro Shimizu, Tetsunari Hase, Masahiro Morise, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa. Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer. European Geriatric Medicine. 2018. 9. 2. 255-262
Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, et al. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. JOURNAL OF THE ENDOCRINE SOCIETY. 2018. 2. 3. 241-251-251
Yasushi Shintani, Seiki Hasegawa, Teruhisa Takuwa, Keisuke Aoe, Katsuya Kato, Nobukazu Fujimoto, Yasuhiro Hida, Masahiro Morise, Yasumitsu Moriya, Takao Morohoshi, et al. Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study. Journal of thoracic disease. 2018. 10. 3. 1968-1971

ｍore...

Books (8)：

肺癌診療ガイドライン 2018年版.
金原出版 2018
肺癌診療ガイドライン 2017年版. IV期非小細胞肺癌薬物療法.
金原出版 2017
EBMの手法による肺癌診療ガイドライン 2016年版
金原出版 2016
胸部X線読影セミナー第7回日本医事新報
日本医事新報社 2013
小細胞肺癌に用いる抗がん剤の副作用;予測と対策
へるす出版 2012

ｍore...

Lectures and oral presentations (18)：

肺癌に対する免疫療法の近未来的展望放射線治療との併用
(第59回日本呼吸器学会学術講演会 2019)
外来肺癌治療の現状と課題
(第28回日本呼吸ケア・リハビリテーション学会学術集会 2018)
The indication of primary prevention for febrile neutropenia (FN) in elderly NSCLC patients treated with docetaxel.
(2016 the Japanese Society of Medical Oncology Annual Meeting 2016)
The efficacy and safety of re-challenge platinum plus pemtrexed combination therapy for recurrent malignant pleural mesothelioma
(16th World Conference on Lung Cancer 2015)
The prophylactic antiemetic treatment failure in patients with lung cancer treated with CBDCA based-chemotherapy
(Japan Society of Medical Oncology Annual meeting 2015 2015)

ｍore...

Education (2)：

- 2010 Nagoya University Graduate School, Division of Medical Sciences
- 2000 Gifu University Faculty of Medicine

Work history (6)：

2019/04/01 - 現在 Nagoya University Nagoya University Hospital Respiratory Medicine Lecturer of hospital
2017/02/01 - 2019/03/31 Nagoya University Nagoya University Hospital Postgraduate Clinical Training and Career Development Support Center, Deputy Director
2017/02/01 - 2019/03/31 Nagoya University Nagoya University Hospital Assistant professor of hospital
2015/01/01 - 2017/01/31 Nagoya University Nagoya University Hospital Center for Postgraduate Clinical Training and Career Development Assistant professor of hospital
2014/04/01 - 2014/12/31 Nagoya University Nagoya University Hospital Respiratory Medicine Assistant professor of hospital

Show all

Committee career (4)：

2016/12 - 現在日本肺癌学会ガイドライン検討委員会薬物療法小委員会委員
2016/12 - 現在日本肺癌学会ガイドライン検討委員会薬物療法小委員会委員
2016 - 現在日本肺癌学会肺癌登録合同委員会悪性胸膜中皮腫登録事業委員
2014/04 - 2016/12 日本肺癌学会ガイドライン検討委員会薬物療法および集学的治療小委員会協力委員

Association Membership(s) (6)：

日本内科学会 , 日本肺癌学会 , 日本呼吸器学会 , 日本臨床腫瘍学会 , International Association for The Study Of Lung Cancer , European Society for Medical Oncology

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page